Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Novel and Emerging Mutations of Sars-Cov-2: Biomedical Implications Publisher Pubmed

Summary: Why do COVID variants hit differently worldwide? A review of SARS-CoV-2 phylogenetic networks shows mutation-driven diversity affects virulence and treatment—guiding targeted vaccines and antivirals for evolving threats. #SARS-CoV2 #ViralGenomics

Mohammadi E1, 2 ; Shafiee F3 ; Shahzamani K4 ; Ranjbar MM5 ; Alibakhshi A6 ; Ahangarzadeh S7 ; Beikmohammadi L8 ; Shariati L8, 9 ; Hooshmandi S11 ; Ataei B7 ; Javanmard SH10
Authors

Source: Biomedicine and Pharmacotherapy Published:2021


Abstract

Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 virus strains has geographical diversity associated with diverse severity, mortality rate, and response to treatment that were characterized using phylogenetic network analysis of SARS-CoV-2 genomes. Although, there is no explicit and integrative explanation for these variations, the genetic arrangement, and stability of SARS-CoV-2 are basic contributing factors to its virulence and pathogenesis. Hence, understanding these features can be used to predict the future transmission dynamics of SARS-CoV-2 infection, drug development, and vaccine. In this review, we discuss the most recent findings on the mutations in the SARS-CoV-2, which provide valuable information on the genetic diversity of SARS-CoV-2, especially for DNA-based diagnosis, antivirals, and vaccine development for COVID-19. © 2021
Other Related Docs
13. The Molecular Basis of Covid-19 Pathogenesis, Conventional and Nanomedicine Therapy, International Journal of Molecular Sciences (2021)
17. Corticosteroid Therapy for 2019 Novel Coronavirus: Lessons From Sars and Mers, Avicenna Journal of Clinical Microbiology and Infection (2021)
18. Potential Treatments for Covid-19; a Narrative Literature Review, Archives of Academic Emergency Medicine (2020)
20. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)